Nigeria: WHO Recommends a Clinical Trial of Ebola Vaccine Against Bundibugyo Virus

What the report says

The World Health Organisation has recommended that the Ebola vaccine Ervebo be prioritised for a randomised clinical trial against Bundibugyo virus disease in the Democratic Republic of Congo. The recommendation was made by WHO’s Technical Advisory Group on Candidate Vaccine Prioritisation at its third meeting on 31 July, after reviewing the vaccine’s safety, efficacy, availability and feasibility.

According to the Premium Times report distributed by AllAfrica, the move follows preliminary animal-study evidence suggesting Ervebo could offer some cross-protection against Bundibugyo virus disease, including a possible reduction in deaths. The vaccine was originally developed for Ebola Zaire virus, not Bundibugyo virus, so WHO has previously been cautious about use outside tightly controlled research settings.

The report says the DRC is responding to an outbreak of Ebola disease caused by Bundibugyo virus, declared on 15 May 2026. WHO had recorded 3,605 confirmed cases and 1,587 deaths as of 30 July. WHO also said there were no identified safety concerns from use among contacts of confirmed cases, but that effectiveness against infection and transmission has not been established.

More broadly, the article notes that WHO still considers a vaccine specifically designed for Bundibugyo virus to be the preferred option, though no licensed vaccine or specific treatment currently exists. The recommendation matters because it could help shape research and future vaccine access if further evidence supports protection against the outbreak strain.